Streetbeat News

Price Targets

DVA

Truist Securities has maintained a Hold rating on DaVita (NYSE:DVA) while raising the price target from $165 to $175, indicating a positive outlook on the stock's potential performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:30 pm

DGX

Truist Securities has maintained a Hold rating on Quest Diagnostics while raising the price target from $158 to $165.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:29 pm

APD

Evercore ISI Group has upgraded Air Products & Chemicals (NYSE:APD) from In-Line to Outperform, raising the price target from $305 to $365.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:22 pm

OHI

BMO Capital has maintained a Market Perform rating on Omega Healthcare Investors (NYSE:OHI) and raised its price target from $44 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:20 pm

CTRE

BMO Capital has maintained an 'Outperform' rating on CareTrust REIT and raised its price target from $33 to $34, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:18 pm

CC

BMO Capital analyst John McNulty maintains an Outperform rating on Chemours (NYSE:CC) and raises the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:15 pm

UROY

B. Riley Securities has initiated coverage on Uranium Royalty (NASDAQ:UROY) with a Buy rating and set a price target of $3.5.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:02 pm

CE

Analysts have recently evaluated Celanese (NYSE:CE), with a variety of opinions ranging from bullish to bearish. The average 12-month price target has decreased by 9.28% to $152.0. Analysts have lowered their ratings and price targets, reflecting challenges such as a decline in revenue and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:01 pm

RYTM

Analysts have provided diverse ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) over the past three months, with a majority being bullish. The average 12-month price target has increased by 9.82% to $60.4. The company has shown significant revenue growth but faces challenges with ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:01 pm

FAST

Five analysts have recently published ratings on Fastenal (NASDAQ:FAST), with a mix of bullish and indifferent sentiments. The average 12-month price target is $71.6, slightly down from the previous $71.67. Analysts have varied in their actions, with some maintaining or lowering their ratings and price targets.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:01 pm